Cardiac troponin I as compared to troponin T for the detection of myocardial damage in horses by Van Der Vekens, Nicky et al.
Cardiac Troponin I as Compared to Troponin T for the Detection of
Myocardial Damage in Horses
N. Van Der Vekens, A. Decloedt, S. Ven, D. De Clercq, and G. van Loon
Background: Diﬀerent cardiac troponin I (cTnI) assays give diﬀerent results. Only 1 manufacturer has marketed troponin
T (cTnT) assays. Therefore, cTnT often is preferred for detection of myocardial infarction in human patients. Studies of
cTnT in horses are limited.
Objectives: To compare a cTnI and a high-sensitive cTnT assay (hs-cTnT) in horses.
Animals: Cardiac troponin I and cTnT were determined in 35 healthy horses (group 1), 23 horses suspected to have pri-
mary myocardial damage (group 2a), and 41 horses with secondary myocardial damage caused by structural heart disease
(group 2b).
Methods: All cTnI samples were analyzed at laboratory A (limit of detection [LOD]: 0.03 ng/mL), whereas cTnT samples
were analyzed at 2 laboratories with the same hs-cTnT assay (laboratory B, LOD: 10.0 pg/mL; laboratory C, LOD: 4.0 pg/
mL).
Results: The median cTnI concentration in group 2a (0.90 ng/mL; range, 0.03–58.27 ng/mL) was signiﬁcantly higher
(P < .001) than in group 1 (0.03 ng/mL; range, 0.03–0.09 ng/mL) or group 2b (0.05 ng/mL; range, 0.03–30.92 ng/mL), and
the optimal cut-oﬀ for detection of primary myocardial damage was 0.095 ng/mL (sensitivity: 90.5%, speciﬁcity: 100%).
Using an LOD of 10.0 pg/mL for all cTnT samples, a cut-oﬀ value of 10.5 pg/mL was found, but sensitivity was low
(42.9%). When only samples analyzed at laboratory C (n = 58) were included, a cut-oﬀ of 6.6 pg/mL was found (sensitivity:
81%, speciﬁcity: 100%).
Conclusions and Clinical Importance: Despite large quantitative diﬀerences, cTnI and cTnT are both useful for detection
of myocardial damage in horses.
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Cardiac troponin I (cTnI) and troponin T (cTnT)have proven to be excellent cardiac biomarkers for
diagnosis of myocardial injury in human medical prac-
tice.1 They have replaced the less sensitive lactate dehy-
drogenase and creatine kinase-myocardial band
enzymes since the 1990s and are routinely used in
human patients for detection of acute myocardial
infarction.2,3 Although cTnI and cTnT have compara-
ble diagnostic eﬃcacy, cTnT often is preferred in
human medicine.3 The existence of a wide variety of
cTnI assays from diﬀerent manufacturers complicates
interpretation and comparison of cTnI data.4 In con-
trast, only Roche Diagnosticsa has marketed cTnT
assays.1,5
The troponin structure is very conserved among spe-
cies. Therefore, assays intended for humans can be
used in horses and other animals.6,7 Over the last
15 years, measurement of cTnI has been introduced in
equine veterinary medicine and several cTnI reference
ranges have been determined by diﬀerent assays.8–13
Studies of cTnT measurement in horses are limited.14–
16 Normal concentrations for cTnT were obtained
in foals with a third generation Elecsys 2010a immuno-
assay16 and in 20 healthy horses, by a qualitative cTnT
assay (Trop T Sensitive Rapid Assaya) and a quantita-
tive cTnT enzyme-linked immunosorbent assayb ,[15] In
this last study, cTnT was increased in horses with car-
diac diseases such as valvular insuﬃciency, endocardi-
tis, and atypical myopathy. However, many horses
with cardiac disease still had cTnT concentrations
under the LOD of the assay (<40 pg/mL). Since 2010,
Roche Diagnostics has marketed a new hs-cTnT
assay.17 Because of its higher sensitivity and increased
precision, this hs-cTnT assay may be a good alterna-
tive for cTnI measurement in horses. Laboratories
often only provide cTnI or cTnT analysis. Therefore,
additional cTnT studies in horses are needed to deter-
mine the applicability of cTnT measurement for the
diagnosis of myocardial damage in horses. The aim of
this study was to establish reference ranges for hs-
cTnT in normal horses and to compare a cTnI with a
hs-cTnT assay in healthy horses and horses with con-
ﬁrmed cardiac disease.
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Materials and Methods
Study Population
This study was approved by the ethics committee of the Faculty
of Veterinary Medicine and Bioscience Engineering (EC2012_57).
All horses were privately owned and examined with the owners’
informed consent. To be included as control horses (group 1,
n = 35), horses had to be healthy and in training, and had to be
free of cardiac disease based on cardiac examination including
echocardiography, electrocardiography (ECG) at rest and during
exercise (Televet 100c ).18 Horses of group 2 (n = 64) were pre-
sented at the Faculty of Veterinary Medicine with cardiac disease.
Data Collection and Analysis
Blood was collected before exercise by jugular venipuncture
using a vacutainer collection tube. Samples were left at room tem-
perature for 30 minutes to allow clotting. Next, they were centri-
fuged for 10 minutes at 2,576 9 g. The serum was transferred into
3 cryovial tubesd and stored at 20°C until sample analysis. Sam-
ples were transported on ice to 3 diﬀerent laboratories (A, B and
C; Fig 1). In laboratory A, all samples were analyzed with the
Beckman Access Accu cTnI assay.e The LOD of this assay was
0.03 ng/mL. Samples from all 99 horses also were analyzed with
the hs-cTnT Troponin T hs assay: 47 samples (21 healthy horses
and 26 horses with cardiac disease) were analyzed in laboratory B
with the Cobas E602 analyzer and 58 samples (20 healthy horses
and 38 horses with cardiac disease) were analyzed in laboratory C
with the Cobas E601 analyzer (Fig 1). Six samples from healthy
horses were analyzed both in laboratories B and C. In laboratory
B, a LOD of 10.0 pg/mL was used. Although the same assay was
used, the LOD of laboratory C was 4.0 pg/mL.
Statistical Analysis
Statistical analysis was performed by commercially available
computer software (SPSSf and MedCalcg ). Because data were not
normally distributed, all results were reported as median and range
(minimum, maximum), unless stated otherwise. Samples with a
cTnI or cTnT concentration under the LOD (eg, <10.0 pg/mL)
were assigned the concentration of the LOD (eg, 10.0 pg/mL).
This allowed inclusion of all samples for further statistical
analysis. Because these samples probably had a lower troponin
concentration than assigned, diﬀerences among groups were likely
not overestimated, but rather underestimated. Initially, we chose
to report all cTnT samples, including samples of laboratory C,
with an LOD of 10.0 pg/mL. Secondly, only cTnT samples of lab-
oratory C were considered, allowing an LOD of 4.0 pg/mL. The
storage time diﬀerence between laboratories was compared by the
nonparametric Friedman test. A nonparametric Mann-Whitney
U-test was used to compare the horses’ age, weight, and height.
The troponin concentrations of group 1, 2a, and 2b were com-
pared by the Kruskal-Wallis and the posthoc Dunn’s test. The
cTnI and hs-cTnT assays were compared after log transformation
with the Spearman correlation test. A receiving operator character-
istic (ROC) curve was established to determine the optimal cut-oﬀ
value for detection of myocardial damage for both assays.
Results
Clinical, Echocardiographic, and Electrocardiographic
Examination
Group 1 (age: 8  4 years; weight: 540  61 kg;
height: 165  6 cm) consisted of 13 geldings, 20 mares,
and 2 stallions; 24 Warmbloods, 10 Trotters, and 1
pony. Group 2 (age: 10  7 years; weight:
507  97 kg; height: 163  10 cm) consisted of 33 geld-
ings, 28 mares, and 3 stallions; 39 Warmbloods, 4
mixed breeds, 5 ponies, 4 Friesians, 3 Trotters, 2 draft
horses, 2 Quarter horses, 2 Spanish horses, 2 Arabian
horses, and 1 Halﬂinger horse. No signiﬁcant diﬀerences
in age, weight, or height were found between horses of
groups 1 and 2. Based on clinical and cardiac examina-
tion, horses of group 2 were divided into 2 subgroups:
horses with primary myocardial disease (inﬂammatory,
toxic, or ischemic myocardial damage) and horses with
secondary myocardial disease caused by structural heart
disease (valvular heart disease, ventricular septal
defects, or aortopulmonary ﬁstula).
Of the 64 horses with cardiac disease, 23 were diag-
nosed with primary myocardial disease and included in
group 2a. Twenty-one horses were suspected to have
atypical myopathy based on the seasonality of the dis-
ease, the presence of Maple trees (Acer pseudoplatanus)
around the pastures, extremely increased muscle enzymes
activity (creatine kinase: median, 69,750 mU/mL, range,
1,200–309,000), and necropsy.19,20 The remaining 2
horses in group 2a were suspected to have primary myo-
cardial disease based on the presence of a large number
of ventricular premature depolarizations (>14/minute) on
ECG and lack of echocardiographic evidence of valvular,
pericardial, or vascular disease. One of these horses also
had ataxia, fever, and decreased systolic function of the
left ventricle. Forty-one horses of group 2 were diagnosed
with structural heart disease and therefore included in
group 2b. The severity of valvular regurgitation in these
horses was graded subjectively on a scale from 1 to 9.21
Grade 1–3 was classiﬁed as trivial regurgitation, grade
4–5 as mild, grade 6–7 as moderate, and grade 8–9 as
severe valvular regurgitation, only horses with moderate
or severe valvular regurgitation were selected. Fourteen
horses had moderate regurgitation and 27 horses severe
regurgitation of ≥1 valves. Within this group, 3 horses
Fig 1. Schematic representation of sample analysis in the diﬀerent
laboratories (LOD, limit of detection; group 1, healthy horses;
group 2a, horses with primary myocardial damage; group 2b,
horses with secondary myocardial damage).
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also had an aortapulmonary ﬁstula and 4 horses had a
ventricular septal defect.
Troponin Analysis
All samples were stored at 20°C according to the
manufacturer’s instructions and thawed only once. A
maximum storage time of 6 months at 20°C was rec-
ommended by the manufacturer for the Access Accu
cTnI assay. The median time until analysis for this
assay was 2 days (range, 0–165 days). The maximum
recommended storage time for the hs-cTnT assay was
12 months at 20°C. The median time until analysis
was 5 days (range, 0–38 days) in laboratory B and
3 days (range, 0–183 days) for the hs-cTnT assay in lab-
oratory C. The storage time of samples for laboratory
A (P = .002) and C (P = .005) was signiﬁcantly shorter
than that of samples for laboratory C. No signiﬁcant
diﬀerence in storage time was found between laboratory
A and laboratory C.
Most healthy horses had cTnI and cTnT concentra-
tions under the LOD (cTnI: 0.03 ng/mL; cTnT:
10.0 pg/mL). The median (range) cTnI concentrations
in horses of group 1, 2a, and 2b were 0.03 (0.03–
0.09) ng/mL, 0.90 (0.03–58.27) ng/mL, and 0.05 (0.03–
30.92) ng/mL, respectively. Horses of group 2a had sig-
niﬁcantly higher cTnI concentrations compared to
horses of group 1 (P < .001) and group 2b (P < .001).
Horses with secondary myocardial disease caused by
structural heart disease (group 2b) also had signiﬁcantly
higher (P = .003) cTnI concentrations than healthy
horses (group 1; Fig 2). Based on the ROC curve
(Fig 3), an optimal cut-oﬀ value for detection of pri-
mary myocardial damage was determined for cTnI
(0.095 ng/mL; area under the curve [AUC]: 0.94; 95%
CI: 0.86–100; P < .001; sensitivity: 90.5%; speciﬁcity:
100%). No signiﬁcant (P = .051) cut-oﬀ value
(0.045 ng/mL) could be determined for detection of sec-
ondary myocardial damage.
The median (range) cTnT concentration also was
signiﬁcantly (P = .001) higher in group 2a (10.0, 10.0–
2,010.0 pg/mL) compared to group 1 (10.0, 10.0–
10.0 pg/mL; P < .001) and group 2b (10.0, 10.0–570 pg/
mL; P = .010) for samples of laboratories B and C. No
signiﬁcant diﬀerence was found between group 1 and
group 2b. The cut-oﬀ value for detection of primary
myocardial damage was 10.5 pg/mL (AUC: 0.71; 0.95%
CI: 0.55–0.88; P = .019). However, a low sensitivity was
found (42.9%; speciﬁcity: 100%). No signiﬁcant
(P = .361) cut-oﬀ value for secondary myocardial dis-
ease could be determined. The cTnT concentrations of
the 6 healthy horses which were analyzed in both labo-
ratories all were below the LOD of laboratories B
(10.0 pg/mL) and C (4.0 pg/mL).
When only samples analyzed in laboratory C (n = 58)
were considered, the median cTnT was 4.0 pg/mL
(range, 4.0–6.0 pg/mL) in healthy horses (n = 20) and a
signiﬁcantly higher (P < .001) cTnT concentration was
found in horses with primary myocardial damage (42.2;
4.0–1,341.0 pg/mL). The median cTnT concentration in
horses with primary myocardial damage also was
signiﬁcantly higher (P = .004) than that in horses with
secondary myocardial damage (4.0; 4.0–13.22 pg/mL).
No signiﬁcant diﬀerence was found between healthy
horses or horses with secondary myocardial damage
(Fig 2). Based on the ROC curve, a signiﬁcant
(P = .001) cut-oﬀ (6.6 pg/mL) could be determined for
detection of primary myocardial damage (AUC: 0.89;
95% CI: 0.78–1.00; sensitivity: 81%; speciﬁcity: 100%).
Comparison of cTnI and cTnT Values
A signiﬁcant correlation between log cTnI and log
cTnT was found (Fig 4). The Spearman correlation
coeﬃcient between the cTnI and hs-cTnT concentra-
tions was 0.621 (P = .01). Thirty-six of all samples had
a cTnI value above the cut-oﬀ.
When only samples analyzed in laboratory C were
considered, the Spearman correlation coeﬃcient
between the cTnI and hs-cTnT assays increased to
0.801. The AUC was not signiﬁcantly diﬀerent between
the cTnI and the cTnT ROC curves (P = .376).
Twenty-three of the 58 samples had a cTnT concentra-
tion above the cut-oﬀ (6.6 pg/mL, Table 1). Four
horses were positive for myocardial damage based on
the cTnI results, whereas the cTnT concentration was
below the cut-oﬀ. Three of these horses had atypical
myopathy and the last horse had severe mitral valve
regurgitation with atrial dilatation caused by rupture of
the chordae tendineae. Two horses had high cTnT con-
centrations with normal cTnI concentrations of which 1
had severe aortic regurgitation and the other atypical
myopathy.
Discussion
Cardiac troponin I is routinely used in equine clinical
practice, but diﬀerent assays produce diﬀerent results.
No such variations exist for cTnT assays because only 1
manufacturer produces these assays. For this reason, a
number of laboratories in human medicine might switch
from cTnI to the new hs-cTnT assay for detection of
cardiac disease, which might decrease the availability of
cTnI measurement in clinical practice.14 Because limited
information about cTnT is available in horses,15,16 the
aim of this study was to compare cTnI and cTnT con-
centrations in horses with and without cardiac disease.
Cardiac troponin I was measured with the Access
Accu assay in 1 laboratory (laboratory A). Measure-
ment of cTnT was performed in 2 laboratories (B and
C) with the LOD set at 10.0 pg/mL and 4.0 pg/mL in
laboratories B and C, respectively (Fig 1). Reference
results for cTnI and cTnT were obtained by blood sam-
ple analysis of healthy horses and, for both cTnI and
cTnT, a signiﬁcant diﬀerence was found between the
healthy horses and those with primary myocardial dam-
age. An optimal cut-oﬀ value could be established for
both cTnI and cTnT. In a previous study, an older, less
sensitive cTnT assay was used with an LOD of 40 pg/
mL.15 All healthy horses had a cTnT concentration
under this LOD. However, in our study, a 10-fold more
sensitive cTnT assay was used and showed that the
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cTnT concentration in healthy horses was much lower
than 40 pg/mL. Although an optimal cut-oﬀ concentra-
tion for primary myocardial disease was established,
sensitivity was low when the LOD of both laboratories
B and C was set at 10.0 pg/mL. However, when only
samples analyzed at laboratory C were included with
the LOD set at 4.0 pg/mL, the optimal cut-oﬀ was
lower and the AUC of the cTnT assay approached the
AUC of the cTnI assay. This cTnT cut-oﬀ concentra-
tion provided similar results to categorize horses in
diﬀerent groups as the cTnI cut-oﬀ concentration
(Table 1). Therefore, cTnI and cTnT both were able to
diﬀerentiate healthy horses from horses with primary
myocardial damage.
Although a signiﬁcant correlation between cTnI and
cTnT was found (Fig 4), quantitative diﬀerences
existed: the optimal cTnI cut-oﬀ concentration for pri-
mary myocardial disease (0.095 ng/mL or 95 pg/mL)
was more than 10 times higher than the cTnT cut-oﬀ
concentration (6.6 pg/mL). Because qualitative results
are comparable (Table 1), the quantitative assay diﬀer-
ence seems less important for diagnosis of myocardial
damage and only demonstrates that the same assay has
to be used if troponins are reanalyzed for patient
re-evaluation.
Similar to the situation in human medicine, it seems
that the diagnostic eﬃcacy of cTnI and cTnT is compa-
rable in horses.3 In our study, 4 horses had high cTnI
concentrations, whereas the cTnT assay result was low:
3 of these horses had atypical myopathy, whereas the
other horse had severe valvular regurgitation. Con-
versely, 2 horses had high cTnT concentrations with a
low cTnI concentration. Because extensive postmortem
examination was not performed on the horses that were
determined to be clinically normal with either test, it
could not be determined whether cTnI or cTnT per-
formed better to detect cardiac disease.
Despite the good sensitivity of the hs-cTnT assay, the
LOD was set at 10.0 pg/mL in laboratory B and
4.0 pg/mL in laboratory C. According to laboratory B,
Fig 2. Comparison of the log cardiac troponin I (n = 99, laboratory A) and T (n = 58, laboratory C) concentration in healthy horses
(group 1), horses with primary myocardial damage (group 2a), and horses with secondary myocardial damage caused by structural heart
disease (group 2b). The cut-oﬀ concentration is demonstrated by the horizontal dotted line. The median troponin concentration within each
group is indicated by a black horizontal bar.
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this higher LOD was chosen as a safety margin. In
human medical practice, cardiac troponins are mostly
measured for the early diagnosis of myocardial infarc-
tion. One beneﬁt of high-sensitive assays is their
improved diagnostic accuracy in the case of early pre-
sentation of patients with chest pain. Patients with a
cTnT concentration above the 99th percentile of a large
reference population are diagnosed with acute myocar-
dial infarction and a hs-cTnT cut-oﬀ concentration of
14.0 pg/mL has been determined.22 Therefore, even with
an LOD of 10.0 pg/mL, the hs-cTnT assay still is useful
for detection of myocardial injury in human patients.
However, myocardial infarction is very rare in equine
medicine and valvular heart disease is most commonly
diagnosed.23 Of a total of 555 horses with various car-
diac diseases, Gehlen et al24 diagnosed valvular heart
disease in approximately 65% of the patients. In our
study, most of the horses with suspected primary myo-
cardial damage (n = 23), such as myocarditis or atypical
myopathy because of Acer pseudoplatanus intoxication,
had cTnI (0.90 ng/mL, 0.03–58.27) and cTnT (42.2 pg/
mL, 4.0–1,341.0) concentrations that were well above
the established cut-oﬀ concentrations. Horses with sec-
ondary myocardial disease caused by structural heart
disease had signiﬁcantly lower cTnI and cTnT concen-
trations. No signiﬁcant cut-oﬀ concentration for struc-
tural heart disease could be determined. However, the
Fig 4. A signiﬁcant correlation (r = 0.621) between the log tropo-
nin I value of the Access Accu cardiac troponin I assay and the
log troponin T value of the high-sensitive troponin T assay of
horses of group 2 was found (P = .01).
Table 1. Cross-tabulation comparing the high-sensitive
troponin T assay of laboratory C (cut-oﬀ: 6.6 pg/mL,
limit of detection: 4.0 pg/mL) and the Access Accu tro-
ponin I assay of laboratory A (cut-oﬀ: 0.095 ng/mL,
limit of detection: 0.03 ng/mL) for detection of myocar-
dial disease.
hs-cTnT
TotalNegative Positive
cTnI
Negative 31 (53%) 2 (3%) 33 (57%)
Positive 4 (7%) 21 (36%) 25 (43%)
Total 35 (60%) 23 (40%) 58 (100%)
hs-cTnT, high-sensitive cardiac troponin T; cTnI, troponin I.
Fig 3. Receiver operator characteristic (ROC) curve of the Access Accu troponin I (cTnI) assay of laboratory A (■ cut-oﬀ = 0.095 ng/
mL), the high-sensitive troponin T (cTnT) assay of laboratory B and C together (● cut-oﬀ = 10.5 pg/mL) and of laboratory C separately
(▲ cut-oﬀ = 6.6 pg/mL) for detection of primary myocardial damage.
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cTnI concentration in horses with secondary myocardial
damage was signiﬁcantly higher than that in healthy
horses. Thus, horses with structural heart disease also
could have minor increases in troponin concentrations.
Two of the 3 horses with aortopulmonary ﬁstulas had
acute clinical signs and a cTnI increase (0.26 and
1.98 ng/mL) of greater extent than most of the other
horses in group 2b. In contrast to valvular heart dis-
ease, aortopulmonary ﬁstulation often is an acute event,
which might cause a sudden and extensive release of
cTnI.
One limitation of our study was that not all cTnT
samples could be analyzed at the same laboratory. Not
only the LOD but also other laboratory characteristics
could have inﬂuenced results. A large study in which
the same samples are analyzed with the same assay in
diﬀerent laboratories could elucidate variation among
laboratories. Samples for cTnI and cTnT also were not
analyzed at the same time. However, all samples were
stored at 20°C, analyzed within the time recom-
mended by the manufacturer, and only thawed once.
CTnT is known to be stable for 3 months at 20°C
and only 9/99 samples were stored >3 months (maxi-
mum 5.5 months). Therefore, the inﬂuence of storage
on our results is most likely minimal.25 Thirdly, it could
be argued that extensive muscle damage caused tropo-
nin increase in horses with atypical myopathy. How-
ever, skeletal muscle damage has no impact on cTnI
concentrations and only has an inﬂuence on ﬁrst gener-
ation cTnT assays26,27 Cardiac damage in atypical
myopathy previously has been identiﬁed by echocardi-
ography, ECG, and necropsy ﬁndings19,20 and was
thought to be the source of the troponin increase in our
study. Finally, it could not be ruled out that the tropo-
nin increase in horses with structural heart disease was
caused by additional primary myocardial damage. How-
ever, no myocardial abnormalities were seen in these
horses during echocardiographic examination.
Conclusion
Both cTnI and cTnT can distinguish healthy horses
from horses with myocardial disease and have compara-
ble diagnostic value. However, absolute cTnI and cTnT
diﬀerences exist, which indicates that the same assay
should be used for patient re-evaluation.
Footnotes
a Roche Diagnostics GmbH, Indianapolis, IN
b ELISA Troponin T, Boehringer, (Manheim, Germany), now
Roche Diagnostics Corporation (Indianapolis, IN)
c Engel Engineering Services GmbH, Oﬀenbach, Germany
d Cryovials 2 mL, VWR International, Leuven, Belgium
e Beckman Coulter Inc, Fullerton, CA
f Version 22.0, Chicago, IL
g Version 13.2.0.0, Ostend, Belgium
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